StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC)

Research analysts at StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. Barclays decreased their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Finally, Mizuho lowered their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Price Performance

NASDAQ RVNC opened at $3.65 on Wednesday. Revance Therapeutics has a 52 week low of $2.30 and a 52 week high of $6.65. The company has a 50 day moving average price of $3.65 and a 200 day moving average price of $4.18. The firm has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Institutional Trading of Revance Therapeutics

Large investors have recently added to or reduced their stakes in the company. CIBRA Capital Ltd acquired a new stake in shares of Revance Therapeutics during the fourth quarter worth about $3,466,000. Alpine Global Management LLC purchased a new position in Revance Therapeutics during the 4th quarter worth approximately $37,000. Two Sigma Investments LP lifted its stake in Revance Therapeutics by 8.6% during the 4th quarter. Two Sigma Investments LP now owns 170,136 shares of the biopharmaceutical company’s stock valued at $517,000 after acquiring an additional 13,539 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Revance Therapeutics by 19.3% in the 4th quarter. ProShare Advisors LLC now owns 75,252 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 12,155 shares during the last quarter. Finally, Man Group plc increased its stake in shares of Revance Therapeutics by 47.8% in the fourth quarter. Man Group plc now owns 443,544 shares of the biopharmaceutical company’s stock worth $1,348,000 after acquiring an additional 143,544 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.